“lundbeck” Archives

in
Entry Author Date Location
Biohaven’s Acute Migraine Drug Bests Placebo in Prevention Study 03/30/20 National
Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More 02/28/20 National
Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug 02/23/20 National
Bio Roundup: Pelosi’s Reveal, Alder’s Deal, Biogen’s Fails & More 09/20/19 National
Eying “Extra” DNA As Cancer Driver, Boundless Bio Debuts With $46M 09/19/19 San Diego
Lundbeck Paying Nearly $2B for Alder to Follow Migraine Rivals to Market 09/16/19 National
Lundbeck to Buy Abide Therapeutics For $250M, Make SD Lab a US Hub 05/06/19 San Diego
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More 03/22/19 National
New Biotech Magnolia Neurosciences Gets $31M For Neuroprotective Drugs 08/13/18 New York
Eisai & Biogen Reveal Promising Alzheimer’s Data, But Questions Linger 07/26/18 Boston
Bio Roundup: Dunsire’s Danish, Price Hikes, Rare-Disease Race & More 07/06/18 National
Lundbeck Reaches Across Atlantic, Picks Dunsire for CEO Post 07/02/18 Boston
With Alzheimer’s Failure, vTv Fares No Better Than Old Partner Pfizer 04/09/18 Raleigh Durham
Alzheon Files for IPO to Fund Studies of Amyloid Alzheimer’s Drug 03/16/18 Boston
23andMe Raises $250M For Consumer Disease-Risk Tests, Drug R&D 09/12/17 San Francisco
With $75M Haul, Ovid Continues Flurry of Biotech IPOs 05/04/17 New York
With Ovid IPO, Ex-Teva CEO Levin Pitches Neuro Drug Plan to Wall Street 04/11/17 New York
Bio Roundup: Travel Ban Block, Gilead Shock, Dean Kamen Talk & More 02/10/17 National
Hunting For Pharma Deals, Ovid Bags Epilepsy Drug from Takeda 01/18/17 New York
East Coast Biotech Roundup: Editas, Checkmate, Ovid & More 08/14/15 Boston
Ex-Teva CEO’s Brain Disease Startup, Ovid, Bags $75M From Crossovers 08/11/15 New York
Ex-Chelsea Tx CEO Oliveto Takes Head Seat at Galleon Pharma 08/04/15 Raleigh Durham
Shire Snaps up New York’s Foresight Bio in $300M Pink Eye Deal 08/03/15 New York
Levin Steps in as Ovid CEO, Confirms Plan to Target Rare Neuro Diseases 04/16/15 New York
Alkermes Scores Phase 3 Win for Long-Lasting Schizophrenia Drug 04/08/14 Boston
With Fluorine Tech, SciFluor Aims to Vindicate “Me-Too” Drugs 02/25/13 Boston
Page 1 of 1